Global Acute Lymphoblastic Leukemia Market - Snapshot

The global acute lymphoblastic leukemia market is driven by the rise in prevalence of acute lymphoblastic leukemia. Expansion of the market is attributed to the increase in cancer awareness programs and strong product pipeline.

acute lymphoblastic leukemia market

Acute lymphocytic leukemia is the most common type of cancer affecting children. Major symptoms of acute lymphoblastic leukemia include bone pain, bleeding gums, fever, pale skin, and fatigue. It is of two types; B-cell acute lymphoblastic leukemia and T-cell acute lymphoblastic leukemia. Treatment of this disease includes chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. Increasing prevalence of acute lymphoblastic leukemia is anticipated to increase the demand for therapeutics, which in turn is expected to drive the global acute lymphoblastic leukemia market. For instance, in 2017 according to National Cancer Institute, the number of new cases of acute lymphoblastic leukemia was approximately 1.7 per 100,000 population in the U.S. Moreover, increase in health care expenditure and rise in number of clinical trials are expected to fuel the global acute lymphoblastic leukemia market.

The global acute lymphoblastic leukemia market has been segmented based on type, treatment, end-user, and region. Based on type, this market has been classified into B-cell and T-cell. The B-cell segment dominated the global market, as around 85% of the total acute lymphoblastic leukemia patients are diagnosed with B-cell acute lymphoblastic leukemia. In terms of treatment, the global market has been classified into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The chemotherapy treatment segment accounted for a major share of the global market, in terms of revenue, in 2017. The segment is projected to expand at a significant CAGR during the forecast period, due to its high prescription rate, wide range of products, and easy availability.

Based on end-user, the global acute lymphoblastic leukemia market has been categorized into hospitals, clinics, and others. The hospitals segment dominated the global market in 2017. The trend is likely to continue during the forecast period. This is attributed to the increase in health care infrastructure, favorable reimbursement policies, and surge in awareness among individuals about acute lymphoblastic leukemia. Moreover, hospitals provide advanced medical treatment to treat acute lymphoblastic leukemia patients.

In terms of region, the global acute lymphoblastic leukemia market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to gain market share by the end of 2026. The market in North America is driven by an increase in incidence of acute lymphoblastic leukemia, new product approvals, strong product pipeline, and rise in health care expenditure. The acute lymphoblastic leukemia market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. Japan dominated the acute lymphoblastic leukemia market in the region. The market in India is expected to expand at a high CAGR during the forecast period.

Major players operating in the global acute lymphoblastic leukemia market include Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Erytech Pharma, Inc., Celgene Corporation, Amgen, Inc. Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc. These companies have adopted the strategy of acquisition and collaboration in order to strengthen their position in the global market.

Global Acute Lymphoblastic Leukemia Market: Overview

This report analyzes the current and future scenario of the global acute lymphoblastic leukemia market. Increase in patient population with acute lymphoblastic leukemia, expansion of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be major drivers of the global market during the forecast period.

The global acute lymphoblastic leukemia market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global acute lymphoblastic leukemia market.

Global Acute Lymphoblastic Leukemia Market: Key Segments

In terms of type, the global acute lymphoblastic leukemia market has been classified into B-cell and T-cell. Based on treatment, the global acute lymphoblastic leukemia market has been segregated into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The segments have been analyzed based on available drug product used during the treatment of acute lymphoblastic leukemia, cost-effectiveness, and preference for industries. In terms of end-user, the global market has been divided into hospitals, clinics, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Acute Lymphoblastic Leukemia Market: Regional Outlook

In terms of region, the global acute lymphoblastic leukemia market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global acute lymphoblastic leukemia market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in the market report include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma Inc., Celgene Corporation, Amgen, Inc. Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc.

The global acute lymphoblastic leukemia market has been segmented as below:

  • Global Acute Lymphoblastic Leukemia Market, by Type
    • B-cell
    • T-cell
  • Global Acute Lymphoblastic Leukemia Market, by Treatment
    • Chemotherapy
    • Radiation Therapy
    • Bone Marrow Transplant
    • Targeted Therapy
    • Immunotherapy
  • Global Acute Lymphoblastic Leukemia Market, by End-user
    • Hospitals
    • Clinics
    • Others
  • Global Acute Lymphoblastic Leukemia Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • Italy
      • France
      • Spain
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Israel
      • Rest of Middle East & Africa
.